Amyloidosis constitutes a large spectrum of diseases characterized by an extracellular deposition of a fibrillar aggregate, generating insoluble and toxic amasses that may be deposited in tissues in bundles with an abnormal cross-β-sheet conformation, known as amyloid. Amyloid may lead to a cell damage and an impairment of organ function. Several different proteins are recognized as able to produce amyloid fibrils with a different tissue tropism related to the molecular structure. The deposition of amyloid may occur as a consequence of the presence of an abnormal protein, caused by high plasma levels of a normal protein, or as a result of the aging process along with some environmental factors. Although amyloidosis is rare, amyloid deposits play a role in several conditions as degenerative diseases. Thus, the development of antiamyloid curative treatments may be a rational approach to treat neurodegenerative conditions like Alzheimer's disease in the future. Nowadays, novel treatment options are currently refined through controlled trials, as new drug targets and different therapeutic approaches have been identified and validated through modern advances in basic research. Fibril formation stabilizers, proteasome inhibitors, and immunotherapy revealed promising results in improving the outcomes of patients with systemic amyloidosis, and these novel algorithms will be effectively combined with current treatments based on chemotherapeutic regimens. The aim of this review is to provide an update on diagnosis and treatment for systemic amyloidosis.

Systemic amyloidosis: a contemporary overview / D'Aguanno, Vittorio; Ralli, Massimo; Artico, Marco; Russo, Francesca Yoshie; Scarpa, Alfonso; Fiore, Marco; Tirassa, Paola; Severini, Cinzia; de Vincentiis, Marco; Greco, Antonio. - In: CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY. - ISSN 1080-0549. - (2019). [10.1007/s12016-019-08759-4]

Systemic amyloidosis: a contemporary overview

D'Aguanno, Vittorio
Primo
;
Ralli, Massimo
Secondo
;
Artico, Marco;Russo, Francesca Yoshie;de Vincentiis, Marco
Penultimo
;
Greco, Antonio
Ultimo
2019

Abstract

Amyloidosis constitutes a large spectrum of diseases characterized by an extracellular deposition of a fibrillar aggregate, generating insoluble and toxic amasses that may be deposited in tissues in bundles with an abnormal cross-β-sheet conformation, known as amyloid. Amyloid may lead to a cell damage and an impairment of organ function. Several different proteins are recognized as able to produce amyloid fibrils with a different tissue tropism related to the molecular structure. The deposition of amyloid may occur as a consequence of the presence of an abnormal protein, caused by high plasma levels of a normal protein, or as a result of the aging process along with some environmental factors. Although amyloidosis is rare, amyloid deposits play a role in several conditions as degenerative diseases. Thus, the development of antiamyloid curative treatments may be a rational approach to treat neurodegenerative conditions like Alzheimer's disease in the future. Nowadays, novel treatment options are currently refined through controlled trials, as new drug targets and different therapeutic approaches have been identified and validated through modern advances in basic research. Fibril formation stabilizers, proteasome inhibitors, and immunotherapy revealed promising results in improving the outcomes of patients with systemic amyloidosis, and these novel algorithms will be effectively combined with current treatments based on chemotherapeutic regimens. The aim of this review is to provide an update on diagnosis and treatment for systemic amyloidosis.
2019
cardiac amyloidosis; etanercept; kinetic stabilization; proteasome inhibitor; systemic amyloidosis; tafamidis
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Systemic amyloidosis: a contemporary overview / D'Aguanno, Vittorio; Ralli, Massimo; Artico, Marco; Russo, Francesca Yoshie; Scarpa, Alfonso; Fiore, Marco; Tirassa, Paola; Severini, Cinzia; de Vincentiis, Marco; Greco, Antonio. - In: CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY. - ISSN 1080-0549. - (2019). [10.1007/s12016-019-08759-4]
File allegati a questo prodotto
File Dimensione Formato  
D'Aguanno_Systemic Amyloidosis_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 4.49 MB
Formato Adobe PDF
4.49 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1410269
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 14
social impact